Although AREG mAb failed to generate any remarkable changes to tumor growth, combination of this antibody with MIT achieved prominent effects in abrogating tumor progression, with the efficiency approaching that manifested by combined use of MIT with a PD‐L1/PD‐1‐targeting antibody. Here, CD274 is linked to neoplasm.